Novartis expects Zolgensma to eventually generate $1.5–2 billion, according to BioPharma Dive. NVS shares were up 1 percent to $83.01 today after announcing the new data.
FDA approved Zolgensma (onasemnogene abeparvovec-xioi) in 2019 for chi…
Novartis expects Zolgensma to eventually generate $1.5–2 billion, according to BioPharma Dive. NVS shares were up 1 percent to $83.01 today after announcing the new data.
FDA approved Zolgensma (onasemnogene abeparvovec-xioi) in 2019 for chi…